RNASET2 and prostate carcinoma: This suggests that RNASET2-overepressing 22Rv1 cells might strongly shape a different macrophage-oriented and tumor suppressive TME, compared with RNASET2-overepressing PC-3 cells, in turn possibly impacting on prostate cancer cell growth in-vivo.